Home > News > BioSante Pharmaceuticals Announces Results
August 16th, 2004
BioSante Pharmaceuticals Announces Results
BioSante reported a net loss of approximately $2.6 million (or $0.15 per share) for the quarter, compared to a net loss of approximately $1.6 million (or $0.18 per share) for the same period in 2003. The increased total net loss was due primarily to increased expenses related to development of the company's hormone therapy products, including the ongoing Phase III clinical trial of Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of menopausal symptoms.
Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014
Acid folic was used in the production of the nanogel as targeting agent in drug delivery. The nanogel can be used in the treatment of cancer as a stable nanocarrier. Stability of nanocarriers is an important issue in target delivery mechanisms. Most of nanocarriers, due to their March 17th, 2014
Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014
Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014